Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Stock Is Printing a New All-Time High Today

By George Budwell – Aug 5, 2020 at 10:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Novavax's COVID-19 vaccine might be the best of the bunch.

What happened

Shares of Novavax (NVAX 1.14%) jumped by as much as 20.7% in pre-market trading Wednesday morning. If this sizable pre-market move holds, the company's shares will easily print a new all-time high today.  

The spark? Novavax's stock is getting yet another boost from its closely watched COVID-19 vaccine candidate known as NVX-CoV2373. Specifically, the biotech reported yesterday that every patient in the first portion of this ongoing phase 1/2 trial exhibited anti-spike IgG antibodies after only a single dose. After a second dose, every patient in the study also developed wild-type virus neutralizing antibody responses to this virus. 

So what

While Novavax is a few months behind the leaders in the race to develop a COVID-19 vaccine, this early stage data suggests that the company might have a best-in-class product. That's a big deal because a top-tier COVID-19 vaccine -- sold at only a modest profit margin -- could haul in some truly staggering sales figures (greater than $13 billion annually).

A man drawing an positive growth curve with his index finger. The year 2020 sits above the apex of the curve.

Image source: Getty Images.

What's more, Novavax might have the option of offering a combination COVID-19 and seasonal flu vaccine at some point down the road. That key development, which may confer a major competitive advantage over some of the biotech's peers, will ultimately depend on the regulatory fate of the late-stage flu vaccine NanoFlu.   

Now what

Can Novavax's stock fly even higher? Although it seems counterintuitive based on the stock's rockstar performance over the past seven months, the truth is that Novavax's shares may have a lot more room to run. COVID-19 isn't going anywhere any time soon according to most experts, and it may even evolve into a long-term seasonal concern.

In short, it wouldn't be surprising in the least if this red-hot biotech stock ended the year at over $300 a share -- or 91% higher compared to where its shares closed on Tuesday. 

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax Stock Quote
$16.83 (1.14%) $0.19

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.